Background: A cardiac lead with a side helix for active fixation to the coronary vein wall (Attain with quantitative traction up to 907 g (2 lbs.) using a locking stylet. Gross pathology and histology of the heart with particular attention to the lead tracts were performed.
INTRODUCTION
Cardiac resynchronization therapy (CRT) system implants continue to be plagued by complications related to the left ventricular (LV) lead, most specifically phrenic nerve stimulation or LV lead dislodgement in 3-10% of patients. [1] [2] [3] [4] [5] Quadripolar LV leads have shown some improvement; however, there remains a need for improved lead stability and site selection in the coronary venous vasculature in order to enhance therapy delivery. Physician implanters have employed methods such as venous stenting, retention of guide wires, or implantation in the coronary veins with active fixation leads designed for the right side of the heart in an effort to enhance lead stability. [6] [7] [8] [9] A novel side helix, active fixation LV lead design (Medtronic Attain Stability R , Model 20066, Medtronic, Minneapolis, MN, USA), which recently received CE Mark, has permitted precise lead placement and also demonstrated excellent lead stability at 12 months in humans. 10, 11 There are a few published case study reports of successful human extraction experiences with the Attain Stability R lead that met Heart Rhythm Society (HRS) guidelines for procedural success. 10, 12, 13 The specific objective of this study was to assess the safety and efficacy of design features of the side helix, active fixation LV lead associated with extraction of chronically implanted leads as compared to a known passive fixation LV lead. The chosen study design, including species, sample size, and implant duration were directly modeled after
Wilkoff et al., whose previously reported extraction experience using implantable cardioverter defibrillator (ICD) leads in sheep implanted for 6 and 14 months serves as a benchmark for lead extractability testing from the coronary sinus and great cardiac vein. 13 Reported here is our experience with the longest-duration animal study and the 
METHODS

Device characteristics
Two types of Medtronic LV lead designs were compared in this study: leads having a side helix active fixation component and a passive fixation unipolar LV lead (Model 4193) as a control. The side helix component was designed such that it could be added to a bipolar or quadripolar LV lead design. The helix of the active fixation LV lead model is not electrically active and is only used for mechanical fixation within the vessel. The fixed helix design attached the lead to the venous wall with clockwise rotation of the lead body. After three-fourth rotation, the helix reaches a mechanical stop that is designed into the helix component to prevent the lead from being overtorqued. Similar to right ventricular (RV) pacing leads, the helix is designed with a tensile strength that will elongate and release from the venous wall well before the helix would separate from the lead body.
The passive fixation, market-released lead (Model 4193, Medtronic) was chosen as the control LV lead, as it has been widely used in the human population. The extraction experience with the passive fixation LV lead has been reported previously. 14, 15 All LV lead models in this study ( Figure 1 ) have a silicone seal at the distal tip to reduce blood ingress. 
Study design
Lead implant method
All surgeries were conducted with the sheep in deep anesthesia. 
Extraction procedure
The lead extraction was performed according to a predefined protocol Continuous pull force data were recorded using a Chatillon force gauge connected to the proximal end of the locking stylet. Continuous tensile force with the lead under traction was measured by the Chatillon relay and displayed via computer throughout the extraction procedure. Applied force targets and duration of traction are described in Figure 2 . The measurement approach was standardized utilizing published extraction reports. 13, [19] [20] [21] Continuous fluoroscopy/cine imaging was recorded throughout the extraction procedure.
Postextraction monitoring
Postextraction monitoring was conducted to assess potential cardiac complications related to the lead extraction procedure. Echocardiograms were performed looking for potential fluid accumulation in the pericardial space. Postextraction images were compared to preextraction images. Postextraction, all animals had cardiopulmonary monitoring for up to 90 minutes before they were heparinized and finally euthanized with an overdose of barbiturate.
Gross examination and histopathology
All sheep underwent a necropsy with careful examination of the heart and the surrounding tissues for any lead-or extraction-associated 
Pathology findings
Necropsy findings in all but one sheep (see below) were all devoid of unusual or unanticipated observations. Notably, there were no gross lesions in association with the side helix fixation site such as epicardial rupture, subepicardial hemorrhage, or vein thrombosis. There was no evidence of sharp trauma from the fixation point back along the course of the venous intima to the jugular insertion site ( Figure 5 ).
F I G U R E 4
Results of the extraction pull forces 
DISCUSSION
Lead stability has been a longstanding concern for patients receiv- The leads (n = 5) were all successfully removed and the authors described similar helix-elongation properties as reported in this study.
Our study prospectively evaluated and compared the extractability of LV leads having a side helix, active fixation feature. The side helix is designed to not only permit stable LV lead positioning, but also to facilitate safe lead extraction. Specifically, the side helix is designed to elongate and straighten under proximal tension, contributing to release from the vessel wall. The novel helix design is intended to minimize the required mechanical extraction forces and the risk of vascular trauma to the level currently observed for passive fixation LV lead extraction.
The median of the peak force required to successfully extract a side helix, active fixation LV lead at 52 weeks in our study was 0.45 kg (range 0.29-0.53 kg, n = 6) and was less than previously reported for a sheep model with ICD leads implanted in the coronary sinus and great cardiac vein (56% > 1 kg, n = 10). 13 In prior sheep extraction publications, 1 kg (2.2 lbs.) has been put forth as the maximum safe pull force that can be applied without countertraction. 13 It appears that the low profile of the solitary side helix elicits a low fibrotic tissue response and less tissue ingrowth than previously reported for the Attain StarFix lead. [22] [23] [24] Visual inspection of the extracted leads with a side helix showed no extracted tissue.
Long-term lead tissue encapsulation in the sheep model was previously evaluated by Wilkoff et al. in a study of extractability of defibrillation leads from the coronary sinus using an implant duration of 6 and 14 months, where it was noted that a mature tissue capsule in the sheep would largely be established with such implant durations. 13 The extraction study design reported here, including chosen animal species, sample size, and implant duration, was modeled after previously published work by Wilkoff et al. 13 While Wilkoff et al. evaluated extractability of ICD leads, they did not directly correlate sheep extraction results to human experience; however, the authors did hypothesize that the sheep provides an accelerated model of fibrotic tissue encapsulation relative to humans, such that humans would require longer lead implant duration to develop a similar amount of fibrous tissue encapsulation. 13 In summary, the side helix, active fixation LV lead design provides stable lead fixation and has extraction characteristics comparable to a standard passive fixation LV lead. The side helix caused only minor, locally restricted, barely detectable perihelical fibrosis and does not appear to increase the risk of vascular injury during the extraction process.
Study limitations
Like the variability in encapsulation exhibited by the human population, the degree of encapsulation observed in animals is known to be variable, and animal models may not reflect human experience. A correlation of the current preclinical findings with clinical extraction outcomes will have to wait for reporting from larger-scale human clinical outcomes.
CONCLUSIONS
The present study represents the longest duration implant experience with subsequent extraction and pathologic assessment that currently exists in the literature for side helix, active fixation LV leads.
In this long-term animal study, side helix, active fixation LV leads demonstrated extraction characteristics at each time point comparable to a standard passive fixation LV lead. All leads, including those implanted >2 years, were explanted with simple traction force of <1 kg.
All extraction procedures met HRS guidelines for complete success.
The active fixation leads maintained positional stability for up to 118 weeks. During extraction, the side helix performed as designed and safely released from the tissue as the helix elongated. No adverse effects were detected by gross or microscopic pathology and there was only minor additional tissue encapsulation at the helix site.
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